Secondary analysis of the data collected through the ACCESS IUS trial, conducted by Medicines360, indicates that rigorous clinical trial data could adequately address common misconceptions about the hormonal IUD, which may be barriers to method use. These slides, originally presented at ICFP 2022, share user outcomes from the trial.

Author: Medicines360